Literature DB >> 21253816

[Successful therapy of sacroiliitis in SAPHO syndrome by etanercept].

Carola Wolber1, Karin David-Jelinek, Astrid Udvardi, Gottfried Artacker, Beatrix Volc-Platzer, Herbert Kurz.   

Abstract

Painful, aseptic osteitis remains the major problem in the treatment of patients with SAPHO syndrome. We present a child suffering of both sacroiliitis and acne conglobata in the context of SAPHO syndrome. While acne lesions responded well to systemic isotretinoin, sacroiliitis associated pain could be controlled neither by NSAR nor by intralesional or systemic steroid injection. Worse pain limited substantially patient's mobility. This changed immediately after starting etanercept. Within a few days, pain resolved and the patient regained his mobility. This favourable response lasted for 8 months when we tried to stop etanercept under protection with the DMARD sulfazalazin. Unfortunately, within a few days, pain and immobility re-occurred requiring reinstitution of etanercept. This case demonstrates that, similar to other reports, TNF blockade is able to induce prompt and long-lasting response of SAPHO syndrome associated osteoarthritis to TNF blockade.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21253816     DOI: 10.1007/s10354-010-0852-8

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  13 in total

Review 1.  The extracutaneous involvement in the neutrophilic dermatoses.

Authors:  M D Vignon-Pennamen
Journal:  Clin Dermatol       Date:  2000 May-Jun       Impact factor: 3.541

2.  Successful treatment of SAPHO syndrome with zoledronic acid.

Authors:  Petros Kopterides; Dimitrios Pikazis; Christos Koufos
Journal:  Arthritis Rheum       Date:  2004-09

3.  Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome treated with a combination of isotretinoin and pamidronate.

Authors:  Hassan Galadari; Alyssa G Bishop; Suraj S Venna; Emad Sultan; Daihung Do; Ross Zeltser
Journal:  J Am Acad Dermatol       Date:  2009-07       Impact factor: 11.527

Review 4.  Pharmacological management of SAPHO syndrome.

Authors:  Ignazio Olivieri; Angela Padula; Carlo Palazzi
Journal:  Expert Opin Investig Drugs       Date:  2006-10       Impact factor: 6.206

Review 5.  Synovitis, acne, pustulosis, hyperostosis, osteitis (SAPHO) syndrome in childhood: a report of ten cases and review of the literature.

Authors:  B C Beretta-Piccoli; M J Sauvain; I Gal; A Schibler; T Saurenmann; H Kressebuch; M G Bianchetti
Journal:  Eur J Pediatr       Date:  2000-08       Impact factor: 3.183

6.  Bisphosphonate treatment in chronic recurrent multifocal osteomyelitis.

Authors:  Peter J Simm; Roger C Allen; Margaret R Zacharin
Journal:  J Pediatr       Date:  2007-11-05       Impact factor: 4.406

Review 7.  [SAPHO syndrome].

Authors:  A M Chamot; M F Kahn
Journal:  Z Rheumatol       Date:  1994 Jul-Aug       Impact factor: 1.372

8.  Clinical and radiologic evolution of synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: a single center study of a cohort of 71 subjects.

Authors:  Matteo Colina; Marcello Govoni; Carlo Orzincolo; Francesco Trotta
Journal:  Arthritis Rheum       Date:  2009-06-15

Review 9.  Ilium osteitis as the main manifestation of the SAPHO syndrome: response to infliximab therapy and review of the literature.

Authors:  Concepción Moll; M Victoria Hernández; Juan D Cañete; José A Gómez-Puerta; Alex Soriano; Antonio Collado; Raimon Sanmartí
Journal:  Semin Arthritis Rheum       Date:  2007-10-31       Impact factor: 5.532

10.  [Acne-pustulosis-hyperostosis-osteitis syndrome. Results of a national survey. 85 cases].

Authors:  A M Chamot; C L Benhamou; M F Kahn; L Beraneck; G Kaplan; A Prost
Journal:  Rev Rhum Mal Osteoartic       Date:  1987-03
View more
  3 in total

1.  Etanercept in the treatment of SAPHO syndrome: Which place?

Authors:  Fatima Ezzahra Abourazzak; Hicham Hachimi; Nadira Kadi; Khadija Berrada; Siham Tizniti; Taoufik Harzy
Journal:  Eur J Rheumatol       Date:  2014-09-01

Review 2.  Current understanding of the pathogenesis and management of chronic recurrent multifocal osteomyelitis.

Authors:  Polly J Ferguson; Monica Sandu
Journal:  Curr Rheumatol Rep       Date:  2012-04       Impact factor: 4.592

Review 3.  Chronic recurrent multifocal osteomyelitis.

Authors:  Patrícia Costa-Reis; Kathleen E Sullivan
Journal:  J Clin Immunol       Date:  2013-05-22       Impact factor: 8.317

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.